Cargando…
Radiopharmaceutical Validation for Clinical Use
Radiopharmaceuticals are reemerging as attractive anticancer agents, but there are no universally adopted guidelines or standardized procedures for evaluating agent validity before early-phase trial implementation. To validate a radiopharmaceutical, it is desirous for the radiopharmaceutical to be s...
Autores principales: | Kunos, Charles A., Howells, Rodney, Chauhan, Aman, Myint, Zin W., Bernard, Mark E., El Khouli, Riham, Capala, Jacek |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7966985/ https://www.ncbi.nlm.nih.gov/pubmed/33747951 http://dx.doi.org/10.3389/fonc.2021.630827 |
Ejemplares similares
-
Radiopharmaceuticals for Relapsed or Refractory Leukemias
por: Kunos, Charles A., et al.
Publicado: (2019) -
Phase 0 Radiopharmaceutical–Agent Clinical Development
por: Kunos, Charles A., et al.
Publicado: (2020) -
Clinical Outcome Assessments Toolbox for Radiopharmaceuticals
por: Kunos, Charles A., et al.
Publicado: (2019) -
Radiopharmaceuticals for Persistent or Recurrent Uterine Cervix Cancer
por: Kunos, Charles A., et al.
Publicado: (2019) -
Radiopharmaceuticals for Relapsed or Refractory Ovarian Cancers
por: Kunos, Charles A., et al.
Publicado: (2019)